Background & Aims: Liver graft injury and tumor recurrence are the major challenges of liver transplantation for the patients with hepatocellular carcinoma (HCC). Here, we aimed to explore the role and mechanism of liver graft injury mobilizing regulatory T cells (Tregs), which lead to late phase tumor recurrence after liver transplantation. Methods: The correlation among tumor recurrence, liver graft injury and Tregs mobilization were studied in 257 liver transplant recipients with HCC and orthotopic rat liver transplantation models. The direct roles of CXCL10/CXCR3 signaling on Tregs mobilization and tumor recurrence were investigated in CXCL10 À/À and CXCR3 À/À mice models with hepatic IR injury. Results: Clinically, patients received the graft with graft weight ratio (GWR) <60% had higher HCC recurrence after liver transplantation than the recipients with GWR P60% graft. More circulating Tregs and higher intragraft TLR4/CXCL10/CXCR3 levels were detected in recipients with GWR <60% graft. These results were further validated in rat transplantation model. Foxp3 + cells and expressions of TLR4, CXCL10, TGFb, CTLA-4 and CD274 were increased in rat liver tumor tissues from small-for-size graft group. In mouse model, the mobilization and recruitment of Tregs were decreased in TLR4 À/À , CXCL10 À/À and CXCR3 À/À mice compared to wild-type mice. Moreover, less CXCR3 + Tregs were recruited into liver in CXCL10 À/À mice after hepatic IR injury. The knockout of CXCL10 and depletion of Tregs inhibited tumor recurrence after hepatic IR injury. Conclusion: CXCL10/CXCR3 signaling upregulated at liver graft injury directly induced the mobilization and intragraft recruitment of Tregs, which further promoted HCC recurrence after transplantation. Lay summary: There were positive correlation among tumor recurrence, circulating Tregs and liver graft injury after human transplantation for HCC patients. The knockout of CXCL10 decreased hepatic recruitment of CXCR3 + Tregs and late phase tumor recurrence after hepatic IR injury. Ó 2016 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Journal of Hepatology 2016 vol. 65 j 944-952
Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent malignancy in the world and the second cause of cancer-related mortality [1] . Liver transplantation is an effective therapeutic modality for the treatment of HCC patients and offers higher long term survival prospects compared to liver resection and local ablation [2] . Living donor liver transplantation (LDLT) has been developed as an alternative choice to overcome the critical shortage of liver grafts from deceased donors, and to shorten the waiting time and decrease waitlist mortality [2] . With the accumulation of liver transplantation for HCC patients, liver tumor recurrence after transplantation has become an important issue affecting the outcomes of liver transplantation [3] . The current opinions regarding the difference in HCC recurrence between LDLT and deceased donor liver transplant (DDLT) remains controversial [4, 5] . Several liver transplantation centers have reported that the tumor recurrence after LDLT is higher compared to DDLT [6] [7] [8] . The liver graft from living donor is usually small-for-size for the recipient, and is associated with a higher incidence of acute-phase liver graft injury [9] . Several studies have demonstrated that liver graft injury promoted tumor cell adhesion, invasion, and angiogenesis [10] [11] [12] . However, the mechanism of liver graft injury promoting late phase tumor recurrence after transplantation has not been well defined.
Liver graft injury is typified as an amplified and deleterious inflammatory response [13] . A multitude of different cytokines and chemokines as well as immune cells are involved in these inflammatory process. Toll-like receptor 4 (TLR4) has been demonstrated to initiate the inflammatory response in hepatic ischemia reperfusion (IR) injury via the activation of IRF3 mediated MyD88-independent signal pathway [14, 15] . C-X-C motif chemokine 10 (CXCL10), a downstream product of TLR4-IRF3 signaling, was also proven to be responsible for inflammatory response during hepatic IR injury [16] . Recent research showed that CXCL10 signaling contributes to melanoma growth and metastasis through regulation of cellular adhesion, invasion and migration properties [17] . Our previous paper also demonstrated that CXCL10 was overexpressed in small-for-size liver graft and promoted HCC invasiveness via regulating endothelial progenitor cells and macrophages [12, 18] . Furthermore, CXCL10 can recruit more regulatory T cells (Tregs) trafficking to the liver through their surface receptor CXCR3 [19, 20] . However, the role and mechanism of CXCL10/CXCR3 signaling in regulating Tregs mobilization and late phase tumor recurrence after liver transplantation are unclear.
Tregs, were first proposed in 1970 as the term for suppressor T cells, which play important roles in maintaining immune tolerance and controlling inflammatory diseases [21, 22] . Tregs exert their suppressive effects either via cell contact dependent manner by membrane-bound molecules or through contact independent manner mainly by release of inhibitory cytokines [23] . Tregs can ligate CD80/CD86 on effector T cells and DCs through CTLA-4, and result in suppression of effector T cells function and T cells deletion [24] . Secretion of inhibitory cytokines such as transforming growth factor (TGF)-b and interleukin (IL)-10 can inhibit T cells proliferation and differentiation as well as suppress macrophages activation and dendritic cell (DC) maturation [25, 26] . In addition, the programmed death-1 receptor (CD279 or PD-1) and its ligand (CD274 or PD-L1) also play important roles in promoting Tregs development and enhancing Tregs function [27, 28] . Recently, Tregs are considered to play critical roles in the induction of transplant tolerance and prevent allograft rejection. Adoptive transfer of Tregs can regulate the rejection response of naïve T cells, prevent allograft rejection and prolong graft survival [29, 30] . This negative regulatory activity, however, can also suppress the immune responses against tumors and thereby promote tumor growth and progress. In the cancer patients, Tregs are significantly mobilized to the peripheral blood and accumulate in tumor regions [31, 32] . Furthermore, the high correlation between frequency of Tregs in cancer patients and their mortality were found in different cancers [32, 33] . The Tregs isolated from the tumor have potent immunosuppressive activity against effector immune cell response and thereby help tumor escape from the host immunosurveillance [34] . However, the effect and mechanism of Tregs in tumor recurrence after transplantation is still unknown. Therefore, strategies aimed to deplete Tregs or to functionally inactivate Tregs is an interesting approach for increasing anti-cancer immunity thereby suppressing tumor growth and recurrence.
In this project, we aimed to study the role and mechanism of acute-phase liver graft injury mobilizing Tregs, which lead to late phase tumor recurrence after liver transplantation. The correlation among liver graft injury, inflammatory cytokines/ chemokines, Tregs mobilization, and tumor recurrence were investigated in both human and rat liver transplantation. The direct roles of CXCL10/CXCR3 signaling on mobilization and recruitment of Tregs together with tumor recurrence were further explored in CXCL10 À/À and CXCR3 À/À mice model with hepatic IR injury.
Materials and methods

Patients and specimens
From 1995 to 2013, 257 patients with HCC received liver transplantation in Department of Surgery, Queen Mary Hospital, The University of Hong Kong, were included in current study. The graft weight ratio (GWR) is the liver graft weight divided by the estimated standard liver weight of the recipient [9] . According to GWR above or below 60%, they were categorized into GWR P60% group (large liver graft, n = 107) and GWR <60% group (small-for-size liver graft, n = 150). The human liver graft biopsy samples were collected at 2 h after portal vein reperfusion and blood samples were collected at day 0, day 7, 1 month, 3 months, 6 months and 12 months after transplantation. The study protocol was approved by the Institutional Review Board of the University of Hong Kong (IRB approval number: UW_11-099). Informed consent was obtained from each patient.
Animal models
Rats and C57BL/6 mice were purchased from the Laboratory Animal Unit, The University of Hong Kong (HKULAU). The TLR4, CXCL10, and CXCR3 knockout mice were described in previous paper [12, 35] . The study had been licensed according to Animal Ordinance Chapter 340 by the Department of Health, Hong Kong Special Administrative Region (ref.: (14-613) in DH/HA&P/8/2/3 Pt. 63).
Rat orthotopic liver transplantation models
Orthotopic rat liver transplantation model using whole graft or small-for-size graft (about 50%) was established [36] . Blood and liver samples were collected at day 1, 3 and 5 respectively after liver transplantation to analyze Tregs mobilization and intragraft recruitment. To detect Tregs and expressions of inflammatory cytokines/chemokines in recurrent tumors, a rat liver transplantation model with tumor recurrence was also used as described in our previously paper [10] . Liver graft samples and liver tumor tissues were collected at day 14 after liver transplantation for further analyses.
Mouse model with major hepatectomy and hepatic IR injury TLR4, CXCL10 and CXCR3 knockout mice and wild-type mice were subjected to major hepatectomy (left and caudate lobes) and partial hepatic IR injury (45 min ischemia of right and triangle lobes), which mimics transplantation with small-for-size liver grafts [37] . Blood and liver samples were collected at day 1, 3 and 5 after reperfusion to analyze Tregs mobilization and intragraft recruitment.
In order to explore the effect of CXCL10 and Tregs on tumor recurrence, mouse HCC cells (Hepa1-6, 1 Â 10 6 /in 100 ll) were injected through portal vein after reperfusion in CXCL10 À/À mouse, to mimic the clinical scenario of circulating tumor cells homing to the graft after liver transplantation. In the group of Tregs depletion, the anti-mouse CD25 antibody (250 lg) was injected into peritoneal at day 1 before operation, and day 5 after hepatic IR injury in wild-type mouse, respectively. Liver tumor tissues were collected at day 14 after the operation.
Detection of circulating Tregs by flow cytometry
The numbers of circulating and hepatic Tregs were detected by flow cytometry. The details of flow cytometry were described in our previous paper [38] . Cells were stained with PE-Cy5-conjugated anti-CD4 (eBioscience, San Diego, CA) and PE-conjugated anti-CD25 (BD Pharmingen, San Diego, CA), and then permeabilized with fixation/permeabilization working solution and incubated with FITC-conjugated anti-Foxp3 (eBioscience, San Diego, CA). The matched isotype controls were also prepared at the same time. Furthermore, the expressions of CTLA-4, CD274, CD279, and CXCR3 in CD4 + CD25 + Tregs were also detected by flow cytometry. The expression levels of CTLA-4, CD274, and CD279 in liver Tregs were expressed by mean fluorescence intensity (MFI).
Isolation of spleen CD4 + CD25 + Tregs
The spleen CD4 + CD25 + Tregs were purified from C57BL/6 and CXCL10 À/À mice using a CD4 + CD25 + Tregs isolation kit (Miltenyi Biotec, GmbH, Germany), according to the manufacturer's recommendation. The CD4 + CD25 + Tregs were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with anti-CD3 (2.5 lg/ ml), anti-CD28 (2.5 lg/ml) and IL-2 (500 U/ml). 3 days later, the expressions of CTLA-4, CD274 and CD279 in spleen Tregs were detected by flow cytometry.
Detection of gene expression by real-time RT-PCR
RT-PCR was done with a modified version of a previous method. Gene expression levels were expressed as the folds relative to the normal liver [37] .
Statistical analysis
The Chi-square test was carried out for the analysis of clinical correlation among graft size clinical features and tumor recurrence after liver transplantation. The correlation among the intragraft expressions of TLR4, CXCL10, CXCR3 and Tregs were analyzed by Spearman correlation. All the comparisons for the study in animals were performed using Student t test. p <0.05 was considered statistically significant. Calculations were performed by using the SPSS computer software version 16.
Results
The tumor recurrence rate was higher in HCC recipients with smallfor-size liver graft
From 1995 to 2013, 257 patients with HCC received liver transplantation in our liver transplantation center. HCC recurrence occurred in 39 recipients after liver transplantation. The clinical parameters related to tumor recurrence were summarized in Table 1 . Among these characteristics, the recurrence of HCC was more frequent in the patients with advanced TNM stage (p = 0.003), beyond Milan and University of California San Francisco (UCSF) criteria (p = 0.007 and p = 0.000 respectively), venous infiltration (p = 0.000), higher serum alphafetoprotein (AFP) (p = 0.001) and positive HBsAg (p = 0.027). In addition, tumor recurrence was also related to GWR (p = 0.028) ( Table 1) . According to GWR, the HCC recipients were categorized into GWR P60% group (large liver graft, n = 107) and GWR <60% group (small-for-size liver graft, n = 150). The comparison of the clinical-pathological characteristics between the HCC recipients in GWR P60% and GWR <60% group were listed in Table 2 . Significant higher cumulative recurrence (29/150 (19.3%) vs. 10/107 (9.3%), p = 0.028) was found in the HCC recipients with small-for-size liver graft after transplantation ( Table 2 ). The percentage of patients with advanced TNM stage, high AFP levels, and beyond Criteria of Milan or UCSF were similar between GWR P60% and GWR <60% groups (Table 2 ). However, the recipients in small-for-size liver graft group had higher venous infiltration (24/102 vs. 57/149, p = 0.014) and less hepatitis B Virus (HBV) positive patients (95/107 vs. 117/150, p = 0.025) ( Table 2 ).
The circulating Tregs were higher in the recipients with small-forsize liver graft and HCC recurrence after human transplantation
Tregs can suppress the immune responses against tumors and thereby promote tumor growth. In order to investigate the mechanism of HCC recurrence after liver transplantation, we analyzed the mobilization of Tregs at different time points after human liver transplantation. Before transplantation, there was no difference of circulating Tregs between the recipients with large liver graft and small-for-size liver graft. The patients received small-for-size liver graft had more circulating Tregs at day 7, 1 months and 3 months after transplantation than those with large liver graft ( Fig. 1A ). Furthermore, more circulating Tregs were also found in patients with HCC recurrence at 1 month, 3 months and 6 months after transplantation than those without HCC recurrence (Fig. 1B) .
Intragraft expressions of inflammatory cytokines/chemokines were increased in the recipients with small-for-size liver graft and HCC recurrence after human transplantation
In order to further explore the mechanism of Treg mobilization after liver transplantation, we compared the expressions of cytokines/chemokines between two groups. Our results indicated that there were significantly higher intragraft TLR4, CXCL10 and CXCR3 expression levels at 2 h after reperfusion in small-forsize liver graft compared with large liver graft ( Fig. 2A ). The expression of CD274 was also upregulated in the small-for-size liver graft ( Supplementary Fig. 1A ). Furthermore, the intragraft expressions of TLR4, CXCL10 and CXCR3 were also significantly higher in the recipients with HCC recurrence compared to those without HCC recurrence ( Fig. 2B ). There were positive correlations among the intragraft expressions of TLR4, CXCL10, CXCR3 and CD274 after transplantation (Supplementary Figs. 1C and 2). Importantly, there were positive correlation among the circulating Tregs and the intragraft expressions of TLR4, CXCL10, and CXCR3 after human transplantation (Fig. 2C ).
Association among inflammatory cytokines/chemokines expressions, Tregs recruitment and tumor recurrence in rat orthotopic liver transplantation (OLT) models
We further compared the circulating mobilization and hepatic recruitment of Tregs between whole liver graft and small-forsize liver graft in rat OLT models. The recipient rats with small-for-size liver graft possessed approximately 2-fold increase of circulating Tregs at day 5 after transplantation vs. whole liver graft ( Fig. 3A) . Consistently, the number of Tregs recruited to small-for-size liver graft was higher than that in whole liver graft (Day 1: 268 cells vs. 139 cells/per 10 5 cells, p = 0.04; Day 5: 1019 cells vs. 480 cells/ per 10 5 cells, p = 0.02) ( Fig. 3B ). Furthermore, compared to whole liver graft group, intragraft mRNA expression level of TLR4 was significantly elevated in small-forsize liver graft on day 3 and 5 after rat transplantation (Supplementary Fig. 3A ). Our previous study also reported that the expressions of CXCL10 and CXCR3 were significantly elevated in small-for-size liver graft after rat transplantation [12] . We already reported greater tumor burden in small-for-size liver graft at day 14 after transplantation compared with whole liver graft in a rat OLT model with tumor recurrence [10] . In current study, we also found that there were more Foxp3 positive cells (8.7 cells vs. 4.7 cells/HPF, p = 0.004) in tumors developed in small-for-size liver graft (Fig. 3C) . After recruitment and homing of Tregs to the tissue, Tregs exerted their suppressive effects either via cell contact dependent manner by membrane-bound molecules or through contact independent manner mainly by release of inhibitory cytokines. Both in tumor and non-tumor tissues, the expressions of TLR4, CXCL10, CD274 and IL-10 were higher in small-for-size liver graft than those in whole liver graft ( Fig. 3D and Supplementary Fig. 3B ). Consistently, the expressions of TGF-b and CTLA-4 were also increased in tumor tissues from small-for-size liver graft ( Supplementary Fig. 3B ). Furthermore, the expressions of TGF-b, CTLA-4, CXCL10, CXCR3, CD274 and CD279 were upregulated in tumor tissues compared to non-tumor tissues ( Fig. 3D and Supplementary Fig. 3B ).
The knockout of CXCL10/CXCR3 signaling reduced the mobilization and recruitment of Tregs
Both the clinical and animal studies showed the correlations among CXCL10/CXCR3 signaling, Tregs mobilization and tumor recurrence after liver transplantation. We then proceeded to investigate the direct role of CXCL10/CXCR3 signaling on Tregs mobilization and recruitment in mouse hepatic IR injury model using TLR4 À/À , CXCL10 À/À and CXCR3 À/À mice. A significant decrease of Tregs mobilization in circulation was observed in TLR4 À/À mice compared to wild-type mice after hepatic IR injury (Day 3: 940 cells vs. 510 cells/per10 5 PBMC, p = 0.04; Day 5: 1134 cells vs. 541 cells/per10 5 PBMC, p = 0.02) (Fig. 4A) . In order to further determine whether the mobilization and recruitment of Tregs after liver injury was dependent on the CXCL10/CXCR3 signaling, CXCL10 À/À mice and CXCR3 À/À mice hepatic IR injury model were applied. The circulating and hepatic Tregs were decreased both in CXCL10 À/À and CXCR3 À/À mice after hepatic IR injury ( Fig. 4B and C) . Before hepatic IR injury, there was no difference of circulating and hepatic Tregs among these knockout mice and wild-type mice.
Furthermore, we also investigated the expressions of TLR4, CXCL10 and CXCR3 in mouse liver after hepatic IR injury and major hepatectomy. The expressions of TLR4, CXCL10 and CXCR3 were significantly elevated in small liver remnant from wild-type mice at day 1, 3 and 5 after hepatic IR injury and liver resection ( Supplementary Fig. 4A-C) . The knockout of TLR4 decreased the hepatic expressions of CXCL10 and CXCR3. The expressions of TLR4 and CXCR3 were also downregulated in the small liver remnant of CXCL10 À/À mice after hepatic IR injury and major hepatectomy ( Supplementary Fig. 4A-C) . Furthermore, the expressions of CD274, CTLA-4 and IL-10 were reduced in TLR4 À/À , CXCL10 À/À and CXCR3 À/À mice compared to wild-type mice ( Supplementary  Fig. 4D-F ). However, there was no significance in TGF-b expression among these knockout and wild-type mice.
The knockout of CXCL10 decreased hepatic recruitment of CXCR3 + Tregs after hepatic IR injury
Since CXCL10 recruits cells via its cognate receptor CXCR3, the cells recruited must express CXCR3. Therefore, we next determined whether CXCR3 + Tregs were recruited into the liver after hepatic IR injury. Before hepatic IR injury, there was similar CXCR3 + Tregs in liver between CXCL10 À/À mice and wild-type mice. The knockout of CXCL10 resulted in a significant decrease in the number of hepatic CXCR3 + Tregs compared with wildtype mice (Day 1: 226 cells vs. 64 cells/per10 5 NPCs, p = 0.03; Day 3: 152 cells vs. 35 cells/per10 5 NPCs, p = 0.01; Day 5: 324 cells vs. 50 cells/per10 5 NPCs, p = 0.00) (Fig. 5A) . On the contrary, the number of circulating CXCR3 + Tregs was higher in CXCL10 À/À mice at day 1 and day 3 after hepatic IR injury compared with wild-type mice (Fig. 5B ). It indicated that knockout of CXCL10 significantly suppressed hepatic recruitment of CXCR3 + Tregs.
The knockout of CXCL10 did not change the expressions of CTLA-4, CD274 and CD279 on Tregs
The association and functional study showed that CXCL10/CXCR3 signaling may contribute to Tregs mobilization and recruitment after liver transplantation. We further investigated the role of CXCL10/CXCR3 signaling on Tregs function both in vivo and in vitro. CTLA-4, CD274 and CD279 expressed in Tregs and play important roles in maintaining and enhancing Tregs function. Firstly, we detected the expressions of CD274, CD279 and CTLA-4 in Tregs recruited to liver after hepatic IR injury. The expression levels of CD274, CD279 and CTLA-4 in liver Tregs after hepatic IR injury were similar in CXCL10 À/À mice and wild-type mice (Fig. 5C-E) . Furthermore, we also examined the role of CXCL10 signaling on the function of the primary spleen Tregs from CXCL10 À/À and wild-type mice. There were comparable percentages of CD274 + , CD279 + and CTLA-4 + spleen Tregs between CXCL10 À/À group and wild-type group ( Supplementary Fig. 5 ).
The knockout of CXCL10 and depletion of Tregs inhibited tumor recurrence after hepatic IR injury
In order to further explore the effects of CXCL10 and Tregs on late phase tumor recurrence, mouse hepatic IR injury model with tumor development was applied. Compared to wild-type mice, the knockout of CXCL10 was significantly inhibited tumor development after hepatic IR injury ( Fig. 6A and B) . At 14 days after hepatic IR injury, hepatic replacement area by tumor was about 60.3% in wild-type mice when compared with 39.6% in CXCL10 À/À mice. Furthermore, we also examined the effect of Tregs depletion on tumor development after hepatic IR injury. The depletion of Tregs by CD25 monoclonal antibody treatment was confirmed ( Supplementary Fig. 6 ). The depletion of Tregs significantly inhibited tumor development after hepatic IR injury ( Fig. 6A and B ).
Discussion
Although liver transplantation is an effective therapeutic modality for the treatment of HCC patients, HCC recurrence after liver transplantation remains a critical issue [2] . The rate of HCC recurrence was significantly higher following LDLT compared to DDLT [7, 8] . However, the precise mechanisms of tumor recurrence after liver transplantation haven't been clearly explored. Therefore, it is worthwhile to reveal the molecular mechanism of tumor recurrence after transplantation and to identify the potential therapeutic target for new treatment.
In this study, we explored for the first time the potential mechanism of Tregs in bridging liver graft injury and tumor recurrence after liver transplantation. In clinical cohort, 15.2% of the HCC recipients occurred tumor recurrence after liver transplantation. The recurrence of HCC was associated with advanced TNM stage, beyond Milan and UCSF criteria, venous infiltration, higher serum AFP and positive HBsAg. In addition, tumor recurrence was also related to GWR. The patients received small-forsize liver graft had significantly higher HCC recurrence incidence than those with large liver graft after transplantation. Our clinical outcome was similar to those with higher recurrence rates following LDLT compared to DDLT from other transplantation centers [7, 8] . Importantly, similar proportion of the recipients with advanced TNM stage, high AFP levels, and beyond Criteria of Milan and UCSF was found between small-for-size graft and large graft. It suggested that small-for-size liver graft itself might be an independent risk factor and contribute to tumor recurrence after liver transplantation.
It has been reported that Tregs play important roles in tumor immunity [33] . There are more Tregs both in circulation and tumor tissues of the patients bearing tumor [39, 40] . Tregs help tumor cells to escape from the host immunosurveillance by their potent immunosuppressive activity against effector immune cell response. Depletion and inhibition of Tregs promote development of tumor immunity and inhibit tumor growth [41, 42] . In our clinical study, more circulating Tregs were found in the patients implanted with small-for-size liver graft and those developed HCC recurrences after transplantation. Consistently, there were more circulating and hepatic Tregs in small-for-size liver graft after rat transplantation. Furthermore, Foxp3 positive cells and expressions of TGF-b, CTLA-4 and CD274 were also increased in the tumor tissues from small-for-size graft group compared to whole graft group. In mouse model, the knockout of CXLC10 also decreased the hepatic expressions of IL-10, CTLA-4, and CD274. Furthermore, the knockout of CXCL10 and depletion of Tregs inhibited tumor recurrence after hepatic IR injury. Tregs can secret inhibitory cytokines such as TGF-b and IL-10, which can inhibit T-cell proliferation and differentiation as well as suppress macrophage activation and DC maturation [26, 33] . CTLA-4-expressing Tregs can suppress effectors T cells by ligating CD80, resulting in the inhibition of T-cell proliferation and cytokine production [43] . In addition, both CD274 and CD279 expressed in Tregs and play important roles in promoting Tregs development and enhancing Tregs function [27] . These results indicated that the mobilization of Tregs by small-for-size graft injury may contribute to HCC recurrence after liver transplantation. The effects of CTLA-4, CD279 and its ligands on Tregs function and their inhibition of anti-tumor immunity need to further studies. The liver graft from a living donor is usually small-for-size for the recipient, and is associated with a higher incidence of acutephase graft injury [9] . Several studies have demonstrated that small-for-size liver graft injury has serious inflammatory response and higher expressions of inflammatory cytokines/ chemokines [9, 16] . In this study, we found that the expressions of TLR4, CXCL10 and CXCR3 were significantly increased in small-for-size liver graft after transplantation both in human and rat. Importantly, the expressions of TLR4, CXCL10 and CXCR3 were correlated with the frequency of circulating Tregs. Recently research showed that CXCL10 can recruit more Tregs trafficking to the liver through their surface receptor CXCR3 after natural killer (NK) cells activation [19] . CXCR3 is expressed on Tregs and mediates Tregs mobilization [20, 44] . However, the effect of CXCL10/CXCR3 in regulating Tregs mobilization and recruitment after liver transplantation has not been clearly explored. We investigated for the first time the direct roles of TLR4, CXCL10 and CXCR3 on mobilization and recruitment of Tregs using TLR4 À/À , CXCL10 À/À and CXCR3 À/À mice underwent hepatic IR injury and major hepatectomy. Significant less circulating mobilization and hepatic recruitment of Tregs were found in TLR4 À/À , CXCL10 À/À and CXCR3 À/À mice. Our results also showed that the number of CXCR3 + Tregs recruitment into the liver was decreased in CXCL10 À/À mice after hepatic IR injury. These results indicated that liver graft injury upregulated intragraft expressions of TLR4 and CXCL10, which further recruited the CXCR3 + Tregs into the liver. We also investigated the effect of CXCL10 signaling in the function of Tregs through in vitro and in vivo experiment. Our results showed that the expression levels of CD274, CD279 and CTLA-4 were similar in liver Tregs after hepatic IR injury and primary Tregs from spleen between CXCL10 À/À group and wild-type group. These results suggested that CXCL10 may only contribute to Tregs mobilization and recruitment but do not change Tregs function. Several studies have demonstrated that other immune cells such as B cells, NK cells and effector T cells can also express CXCR3 and mediates these cells mobilization [45, 46] . The effect of CXCL10 on other immune cells mobilization and their roles in liver tumor recurrence after transplantation will be definitely worthwhile for further studies.
In conclusion, we first defined the correlation among liver graft injury, Tregs and late phase tumor recurrence after liver transplantation. Post-transplant enhanced CXCL10/CXCR3 signaling in acute-phase liver graft directly induced the mobilization and recruitment of Tregs, which further promoted liver tumor growth and recurrence after transplantation. Therefore, targeting at CXCL10/CXCR3 signaling may attenuate acute-phase liver graft The number of circulating CXCR3 + Tregs was higher in CXCL10 À/À mice at day 1 and day 3 after hepatic IR injury compared to WT mice. (C) The expression levels of CTLA-4, CD274 and CD279 in liver Tregs after liver IR injury were similar between CXCL10 À/À mice and WT mice. (N = 3-5/group; ⁄ p <0.05.) injury induced Tregs mobilization and recruitment, and then prevent late phase tumor recurrence. 
Financial support
